Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Subcutaneous Rituximab Seems Headed For US FDA Advisory Panel OK

Mar 28 2017

• By Michael Cipriano

Related Content

First Biosimilar MabThera One Step Away from EU Approval; Pegfilgrastim Filings Withdrawn

Dec 20 2016

Celltrion's Biosimilar Strategy Includes Simultaneous EMA/FDA Reviews

Oct 07 2016

Related Companies

Genentech, Inc.

Roche Holding AG

Halozyme Therapeutics, Inc.

Celltrion, Inc.

Additional Topics

United States Advisory Committees Drug Review Regulation BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window